We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nova Biomedical Demonstrates Whole Blood Critical and POC Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: Stat Profile Prime Plus  (Photo courtesy of Nova Biomedical)
Image: Stat Profile Prime Plus (Photo courtesy of Nova Biomedical)

Nova Biomedical (Waltham, MA, USA) demonstrated its whole blood critical and POC testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

The event provided an unparalleled opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology & vital research in the field.

Nova is a world leader in whole blood critical and POC testing, offering hospital meters (including StatStrip Glucose, the only FDA-cleared meter for critically ill testing) and Stat Profile Prime critical care blood gas analyzers. At AACC 2021, Nova demonstrated its Stat Profile Prime Plus - a comprehensive, whole blood critical care analyzer that offers blood gases, electrolytes, metabolites, hematology, and co-oximetry, in a simple, compact device. Prime Plus combines maintenance-free, replaceable cartridge technology for sensors and reagents with patented, maintenance-free, and non-lysing whole blood co-oximetry technology. The analyzer uses a small 135µL sample, produces a complete 22-test panel in about one minute, and offers automated quality control with real-time, supplement quality monitoring of each sample analysis, calibration, and QC analysis. Prime Plus is the only critical care analyzer that includes BUN, creatinine, ionized magnesium, estimated plasma volume, and MCHC in its test menu. The complete test menu includes pH, PCO2, PO2, Na, K, Cl, iCa, iMg, Glucose, Lactate, BUN/Urea, Creatinine, Hct, Hb, estimated Plasma Volume, MCHC, SO2%, and CO-Oximetry.

At AACC 2021, Nova also displayed the StatStrip Glucose Hospital Meter, which is the only glucose meter cleared by the FDA for use with critically ill patients and CLIA-waived for use with ALL patients and ALL sample types. StatStrip Glucose has no known interferences and brings lab-like accuracy to bedside glucose testing - accuracy validated in an FDA submission study of 1,698 critically ill patients with 257 different and specific medical conditions, and over 8,000 medications, as well as over 200 published studies worldwide. StatStrip Glucose measures glucose and corrects for hematocrit, maltose, and other interferences that can cause erroneous results on other meters.

Related Links:
Nova Biomedical 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more